Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation CADTH. Saxagliptin (Onglyza - Bristol-Myers Squibb/AstraZeneca Canada Inc.) indication: type 2 diabetes mellitus. Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH). CDEC final recommendation. 2014 Authors' conclusions The Canadian Drug Expert Committee (CDEC) recommends that saxagliptin be listed if the following clinical criterion and condition are met:
1. Added on to metformin and a sulfonylurea for patients with inadequate glycemic control on metformin and a sulfonylurea and for whom insulin is not an option.
2. Drug plan costs for saxagliptin should not exceed the cost of other dipeptidyl peptidase-4 (DPP-4) inhibitors. Indexing Status Subject indexing assigned by CRD MeSH Adamantane; Diabetes Mellitus, Type 2s; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors Language Published English Country of organisation Canada English summary An English language summary is available. Address for correspondence Canadian Agency for Drugs and Technologies in Health (CADTH), 865 Carling Avenue, Suite 600, Ottawa, Ontario Canada, K1S 5S8 Email: requests@cadth.ca AccessionNumber 32014000842 Date abstract record published 17/07/2014 |